Last updated: 2026-09-06 01:10:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Medicinova, Inc. (MNOV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,62, with a market capitalization of $70,39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,17 to $1,96. This page covers its latest market performance, valuation, price trends and company information.
$70,39M | |
$1,62 | |
$16,12 | |
$1,12 | |
$1,62 | |
96,56K | |
-- | |
-- | |
$1,96 | |
$1,17 | |
-- | |
-- |
Medicinova, Inc. (MNOV) last closed at $1,62 as of 2026-09-04 23:49:00, unchanged from the previous close of $1,62.
During the latest regular trading session, MNOV traded between $1,12 and $16,12, with a volume of 96,56K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Medicinova, Inc. (MNOV) moved from $1,43 to $1,62, representing a gain of 12,94% ($0,19).
The stock traded between $1,56 and $1,63 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 43,32 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 56,4%
MNOV is currently trading at $1,62, placing it 56,4% of the way from its 52-week low of $1,17 to its 52-week high of $1,96. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Medicinova, Inc. (MNOV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.